Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TRIZIVIR safely and effectively. See full prescribing information for TRIZIVIR. TRIZIVIR (abacavir sulfate, lamivudine, and zidovudine) Tablets, for oral useInitial U.S. Approval: 2000
Medication labelWhy this: Advisory · dailymed-prescription
TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Additional important information on the use of TRIZIVIR for treatment of HIV-1 infection: •TRIZIVIR is one of multiple products containing abacavir. Before starting TRIZIVIR, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1), Adverse Reactions (6)]. •TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3 components. •Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)].
- generic_name
- abacavir sulfate, lamivudine, and zidovudine
- product_names
- abacavir sulfate, lamivudine, and zidovudine
- ndc
- 53808-0990, 49702-217, 53808-0990-1
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en